October 21 Weekly Round-Up: NEC Members Contribute to COVID-19 Crisis Response
As our region and our nation continue to grapple with the Coronavirus Disease (COVID-19) pandemic, The New England Council is using our blog as a platform to highlight some of the incredible work our members have undertaken to respond to the outbreak. Once a week, we’ll post a round-up of updates on some of the initiatives underway among Council members throughout the region. We are also sharing these updates via our social media, and encourage our members to share with us any information on their efforts so that we can be sure to include them in these weekly round-ups.
Eli Lilly Find Drug to Improve Clinical Outcomes – Eli Lilly and Company has found that baricitinib, used alongside remdesivir, reduces recovery time and improves clinical outcomes for patients infected with COVID-19 more so than patients treated only with remdesivir. Eli Lilly originally developed baricitinib – marketed at Olumiant – as a treatment for rheumatoid arthritis, but has been studying the drug as a COVID-19 treatment as part of a trial sponsored by the National Institute of Allery and Infectious Diseaseas (NIAID). The most signifiant impact was observed in patients placed on supplemental oxygen. Read more here.
Harvard Street Neighborhood Health Center Utilizes Mobile COVID-19 Testing Unit – Early in the pandemic, Harvard Street Neighborhood Health Center launched a mobile COVID-19 testing unit, which has since tested thousands of patients at Dudley Square, Prince Grand Hall Lodge, Children’s Services of Roxbury, and other locations. Read more here.
Blue Cross Blue Shield of Massachusetts Grants Additional $400,00 to COVID-19 Fund – Blue Cross Blue Shield has donated $400,000 to go towards supporting communities of color most affected by the pandemic, as well as Massachusetts regional funds community health centers, nonprofits, and teacher organizations. Read more here.